Does Dr. AMBER ANWAR have financial conflicts of interest?

Dr. AMBER ANWAR (M.D.) has received a total of $1,079 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $1,079 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. AMBER ANWAR?

According to CMS Open Payments data, Dr. AMBER ANWAR received funding from OTSUKA AMERICA PHARMACEUTICAL ($179), NOVARTIS PHARMACEUTICALS CORPORATION ($127), and APELLIS PHARMACEUTICALS ($122).

Does Dr. AMBER ANWAR receive research grants or speaking fees?

Dr. AMBER ANWAR has received $1,079 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. AMBER ANWAR

M.D.Real-Time Hydrated

Specialty: Internal Medicine, Nephrology

Practice Location: TAMPA, FL 33614

NPI Number: 1336341692

LIFETIME INDUSTRY VALUE

$1,079

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. ANWAR is a verified Internal Medicine, Nephrology practitioner based in TAMPA, FL.

Between 2021 and 2025, Dr. ANWAR had an overall industry promotional and research financial footprint of $1,079 as recorded in the federal CMS Open Payments database.

$1,079 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ANWAR's primary funding source is OTSUKA AMERICA PHARMACEUTICAL, which accounts for $179 (representing 16.6% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

OTSUKA AMERICA PHARMACEUTICAL

Rank 1

$179

16.6%

NOVARTIS PHARMACEUTICALS CORPORATION

Rank 2

$127

11.7%

APELLIS PHARMACEUTICALS

Rank 3

$122

11.3%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.